Short Interest in Altamira Therapeutics Ltd. (NASDAQ:CYTO) Grows By 9.0%

Altamira Therapeutics Ltd. (NASDAQ:CYTOGet Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 61,700 shares, a growth of 9.0% from the February 29th total of 56,600 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 0.1 days. Approximately 3.9% of the company’s shares are short sold.

Institutional Investors Weigh In On Altamira Therapeutics

A number of institutional investors have recently made changes to their positions in CYTO. Citadel Advisors LLC purchased a new stake in shares of Altamira Therapeutics in the 2nd quarter valued at $47,000. BlackRock Inc. boosted its stake in shares of Altamira Therapeutics by 84.2% in the 1st quarter. BlackRock Inc. now owns 61,603 shares of the company’s stock valued at $67,000 after purchasing an additional 28,151 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of Altamira Therapeutics in the 3rd quarter valued at $203,000. Hedge funds and other institutional investors own 1.91% of the company’s stock.

Altamira Therapeutics Price Performance

Shares of Altamira Therapeutics stock traded down $0.06 during trading on Tuesday, reaching $2.05. The company’s stock had a trading volume of 112,894 shares, compared to its average volume of 1,172,966. Altamira Therapeutics has a 52-week low of $1.61 and a 52-week high of $52.00. The firm’s 50-day moving average is $1.92 and its two-hundred day moving average is $3.36.

Altamira Therapeutics Company Profile

(Get Free Report)

Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells.

Featured Stories

Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with's FREE daily email newsletter.